ChemicalBook--->CAS DataBase List--->706808-37-9

706808-37-9

706808-37-9 Structure

706808-37-9 Structure
IdentificationBack Directory
[Name]

belatacept
[CAS]

706808-37-9
[Synonyms]

belatacept
Research Grade Belatacept (DHE03402)
Chemical PropertiesBack Directory
[form ]

Solid
[color ]

White to off-white
Hazard InformationBack Directory
[Description]

Belatacept is an immunosuppressive that was approved by the U.S. FDA for prophylactic prevention of rejection in kidney transplant recipients. Belatacept, which selectively blocks T cell costimulation, provides an alternative to the calcineurin inhibitors, which are associated with adverse effects on renal function as well as cardiovascular and metabolic parameters. T-cell activation by antigen-presenting cells (APCs) requires a costimulatory signal in addition to the signal mediated by interaction of the T-cell receptor and MHC-bound peptide antigen. Belatacept can block that second signal by binding to APC costimulatory surface proteins CD80 and CD86 to inhibit their interaction with the T-cell signaling molecule CD28. Belatacept is a recombinant protein comprising a hinge-region modified (to reduce Fc receptor binding) carboxylterminal human IgG1 Fc domain fused to a modified extracellular domain of human CTLA-4 that includes two amino acid substitutions in the ligand-binding site. As a result of this modification, belatacept binds more tightly to CD80 and CD86 than the parent molecule abatacept (Orencia, FDA approved for treatment of adult RA and juvenile idiopathic arthritis), from which its structure is derived. CTLA-4 is a T-cell negative signaling molecule that is structurally related to CD28 and shares its two ligands. While belatacept incorporates CTLA-4 sequences to bind CD80 and CD86, the immunosuppressive activity of the drug suggests that its principal mechanism of action is blockade of CD28-mediated T-cell activation.
[Originator]

Bristol-Myers Squibb (United States)
[Uses]

Prevention of allograft rejection in recipients of solid organ transplants; prevention of graft-vs-host disease following bone marrow transplantation; treatment of autoimmune diseases and conditions such as rheumatoid arthritis and Type 1 diabetes.
[Brand name]

Nulojix
[Clinical Use]

Prevents T-cell activation

Prophylaxis of renal transplant rejection
[Drug interactions]

Potentially hazardous interactions with other drugs Vaccines: avoid concomitant use with live vaccines.
[Metabolism]

Because the drug is a protein, belatacept is degraded into smaller peptides and amino acids by proteolytic enzymes.
706808-37-9 suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Website: https://www.bocsci.com
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Website: http://www.chemstan.com/
Company Name: Biolab Reagents  
Tel: 18108604356
Website: www.biolabreagent.com/
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Website: https://www.targetmol.cn/
Company Name: Atagenix Laboratories  
Tel: 027-87008169 17762441161
Website: www.abinscience.com/
Company Name: AntibodySystem Laboratories SAS  
Tel: 33175446423
Website: www.antibodysystem.com
Company Name: Guangzhou Kati Biotechnology Co., Ltd.  
Tel: 13128698830
Website: www.chemicalbook.com/ShowSupplierProductsList1960987/0_EN.htm
Tags:706808-37-9 Related Product Information

  • HomePage | Member Companies | Advertising | Contact us | Previous WebSite | MSDS | CAS Index | CAS DataBase | Privacy | Terms | About Us
  • All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
    According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.
  • Copyright © 2023 ChemicalBook All rights reserved.